Trade Gilead ^GILD

Gilead Sciences, Inc. $GILD Shares Bought by China Universal Asset Management Co. Ltd.

Gilead Sciences (NASDAQ:GILD) Releases Quarterly Earnings Results, Beats Estimates By $0.36 EPS

What Gilead Sciences (GILD) Said on Its Q3 Earnings Call

Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations

Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028

Cognizant Q3 2026 Revenue Rises 4.6% to $5.66 Billion as AI, Banking and Cloud Deals Drive Growth

Gilead Sciences Inc. Announces Retreat In Q3 Income

Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength | Morningstar

Gilead Sciences Q3 26 Earnings Conference Call At 4:30 PM ET

Gilead Sciences, Inc. $GILD Holdings Lowered by Conning Inc.

Gilead Sciences, Inc. $GILD Shares Acquired by Bokf Na

Triple Negative Breast Cancer Market Size in the 7MM is projected to grow at a CAGR of 13.3% over the forecast period of 2026-2036 | DelveInsight | ABNewswire

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead

Gilead Sciences (NASDAQ:GILD) Reaches New 52-Week High - Here's What Happened - Daily Political

3,973 Shares in Gilead Sciences, Inc. $GILD Bought by Leo Wealth LLC - Stock Observer

Gilead buys oral IL-23R inhibitor programme from China's PepStar for $1.27 B

Pharmaceutical Stocks To Research - October 27th - Zolmax

Gilead (GILD) Stock Could Be 50% Undervalued On New Oncology Trial News

Biotech Stocks To Watch Now - October 27th - Markets Daily

Gilead Reaches Canadian Reimbursement Deal For Liver Disease Drug Lyvdelzi

Gilead Successfully Completes Negotiations With Pan-Canadian Pharmaceutical Alliance For LYVDELZI

Canadians Living with Primary Biliary Cholangitis (PBC) One Step Closer to New Treatment Option as Gilead Reaches Milestone National Agreement for LYVDELZI® (seladelpar)

Avantis U.S. Large Cap Value (AVLV) Sells $42.9 Million More MetLife on Friday

ETFs Are Net Sellers of Gilead Sciences (GILD) on Oct. 23

Gilead Sciences (GILD) Could Be 24% Above Fair Value As Settlement News Lands

Gilead Sciences (GILD) Expected to Post Earnings on Thursday - Daily Political

Best Biotech Stocks Worth Watching - October 26th - Markets Daily

Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? | Currency News | Financial and Business News | Markets Insider

Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake

FY2026 EPS Estimate for Gilead Sciences Increased by Analyst

Medical Stocks Worth Watching - October 22nd - Markets Daily

Medical Stocks To Add to Your Watchlist - October 24th - Markets Daily

Investment House LLC Sells 12,165 Shares of Gilead Sciences, Inc. $GILD

Sterling Capital Management LLC Acquires 88,344 Shares of Gilead Sciences, Inc. $GILD - Stock Observer

7,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A. - Daily Political

Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

Interpath-100: data leak, stock drop, spirited defense by ESMO president

3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street

Reviewing Akebia Therapeutics (NASDAQ:AKBA) and Gilead Sciences (NASDAQ:GILD) - Zolmax

Gilead Sciences, Inc. $GILD Stock Holdings Raised by Royal Fund Management LLC - Zolmax

Gilead Sciences, Inc. $GILD Stock Bought by Royal Fund Management LLC

Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash

Gilead Sciences, Inc. $GILD Stock: AMF Tjanstepension AB Lowers Holdings

Gilead expands in I&I with $1.28B Pepstar deal for oral IL-23Ri | BioWorld

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma

Gilead Acquires Oral IL-23R Inhibitor Program for $1.275 Billion in Cash | Morningstar

Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?

BioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Morningstar

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

Gilead Sciences (GILD) Set to Post Quarterly Earnings on Thursday

Gilead Sciences, Inc. $GILD Stock Sold by Crossmark Global Holdings Inc. - Stock Observer

Gilead Sciences, Inc. $GILD Stock: Robeco Institutional Asset Management B.V. Reduces Stake

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Target Price of $159.63

Gilead Sciences, Inc. $GILD Stock Sold by Nisa Investment Advisors LLC

Gilead's Emvistegrast Pill Shows Promising Results in Clinical Trial for Ulcerative Colitis, ETPharma

Gilead Sciences, Inc. $GILD Stock: Range Financial Group LLC Boosts Holdings - Daily Political

Gilead Sciences, Inc. $GILD Stock: Robeco Institutional Asset Management B.V. Trims Stake - Daily Political

Biotech Stocks To Keep An Eye On - October 18th - Stock Observer

Population-level impact of doxycycline post-exposure prophylaxis on bacterial sexually transmitted infections

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Bank of America Analyst Says - Zolmax

Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Bank of America

15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC

How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals

Gilead Sciences, Inc. $GILD Holdings Decreased by Foundation Resource Management Inc. - Zolmax

Gilead Sciences, Inc. $GILD Shares Sold by Foundation Resource Management Inc. - Daily Political

43 ETFs Add to Gilead Sciences (GILD) on Thursday

Gilead's pill succeeds in mid-stage bowel disease trial

Rare prostate cancer histologies: detection, characteristics and treatment

Best Medical Stocks To Consider - October 18th - Markets Daily

Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? - AOL

Gilead Sciences, Inc. $GILD Stake Cut by TD Waterhouse Canada Inc.

Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative? - Simply Wall St News

Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.

Promising Medical Stocks To Research - October 14th

Cognizant Technology Solutions (CTSH) Is Back In The Spotlight, What Is Drawing Attention?

Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Stock

Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares of Company Stock

What Could Gilead Sciences (GILD) New Solid Tumor Partnership Mean For Oncology?

Ninety One UK Ltd Buys New Shares in Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Shares Climb 3.9% - Time to Buy? - Stock Observer

Gilead Sciences, Inc. $GILD Stake Trimmed by Curated Wealth Partners LLC - Zolmax

Gilead Sciences, Inc. $GILD Shares Sold by Curated Wealth Partners LLC

Gilead Sciences Inc. (GILD) - Insider Monkey

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets | Morningstar

Gilead Sciences On Track for Record High Close - Data Talk | Morningstar

Case: Trademarks/Injunctions (4th Cir.)

Vir Biotechnology and Gilead Sciences Forge $1.88 Billion Collaboration for Solid Tumor Cancer Therapies, ETPharma

Stock Market Movers: Best and Worst Performers of 14 October 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Up 3.9% - What's Next?

Vir partners with Gilead in $1.8B+ deal for T-cell engagers